Next Article in Journal
Immune Landscape of Breast Cancers
Previous Article in Journal
Photodynamic Therapy Activated by Intense Pulsed Light in the Treatment of Nonmelanoma Skin Cancer
Previous Article in Special Issue
Site-Specific Antibody Conjugation for ADC and Beyond

Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives

Department of Experimental, Diagnostic and Specialty Medicine-DIMES, Alma Mater Studiorum, University of Bologna, Via San Giacomo 14, 40126 Bologna, Italy
Department of Diagnostic and Interventional Radiology, The “Rizzoli” Orthopaedic Institute, Via G. C. Pupilli 1, 40136 Bologna, Italy
Author to whom correspondence should be addressed.
These authors contributed equally to the work.
Biomedicines 2018, 6(1), 19;
Received: 12 January 2018 / Revised: 30 January 2018 / Accepted: 4 February 2018 / Published: 10 February 2018
(This article belongs to the Special Issue Immunoconjugates)
Osteosarcoma (OS) is an aggressive osteoid-producing tumor of mesenchymal origin, which represents the most common primary bone malignancy. It is characterized by a complex and frequently uncertain etiology. The current standard care for high-grade OS treatment is neoadjuvant chemotherapy, followed by surgery and post-operative chemotherapy. In order to ameliorate survival rates of patients, new therapeutic approaches have been evaluated, mainly immunotherapy with antibody-drug conjugates or immunoconjugates. These molecules consist of a carrier (frequently an antibody) joined by a linker to a toxic moiety (drug, radionuclide, or toxin). Although several clinical trials with immunoconjugates have been conducted, mainly in hematological tumors, their potential as therapeutic agents is relatively under-explored in many types of cancer. In this review, we report the immunoconjugates directed against OS surface antigens, considering the in vitro and in vivo studies. To date, several attempts have been made in preclinical settings, reporting encouraging results and demonstrating the validity of the idea. The clinical experience with glembatumumab vedotin may provide new insights into the real efficacy of antibody-drug conjugates for OS therapy, possibly giving more information about patient selection. Moreover, new opportunities could arise from the ongoing clinical trials in OS patients with unconjugated antibodies that could represent future candidates as carrier moieties of immunoconjugates. View Full-Text
Keywords: osteosarcoma; immunoconjugates; immunotherapy; cancer therapy osteosarcoma; immunoconjugates; immunotherapy; cancer therapy
Show Figures

Graphical abstract

MDPI and ACS Style

Mercatelli, D.; Bortolotti, M.; Bazzocchi, A.; Bolognesi, A.; Polito, L. Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives. Biomedicines 2018, 6, 19.

AMA Style

Mercatelli D, Bortolotti M, Bazzocchi A, Bolognesi A, Polito L. Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives. Biomedicines. 2018; 6(1):19.

Chicago/Turabian Style

Mercatelli, Daniele; Bortolotti, Massimo; Bazzocchi, Alberto; Bolognesi, Andrea; Polito, Letizia. 2018. "Immunoconjugates for Osteosarcoma Therapy: Preclinical Experiences and Future Perspectives" Biomedicines 6, no. 1: 19.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop